Pipeline

Pioneering Treg-Targeted Therapies

Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction:
Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Links